<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.01">
 <iati-activity default-currency="CAD" hierarchy="1" iati-activities:version="2.01" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>XM-DAC-301-2-105880-006</iati-identifier>
  <reporting-org ref="XM-DAC-301-2" type="15">
   <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
   <narrative xml:lang="ES">Centro Internacional de Investigaciones para el Desarrollo</narrative>
   <narrative xml:lang="EN">International Development Research Centre</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">HIV/AIDS Prevention Trials Capacity Building Grants - Phase II</narrative>
   <narrative xml:lang="FR">Subventions de renforcement des capacit&#xE9;s en vue d&apos;essais en mati&#xE8;re de pr&#xE9;vention du VIH/sida - phase III</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="FR">En d&#xE9;cembre 2007, le Programme commun des Nations Unies sur le VIH/sida estimait que pr&#xE8;s de 33,2 millions de personnes vivent avec le VIH dans le monde, dont 68 % en Afrique o&#xF9; le sida est la principale cause de d&#xE9;c&#xE8;s. L&apos;intervention du Canada &#xE0; l&apos;&#xE9;gard de l&apos;&#xE9;pid&#xE9;mie de VIH/sida &#xE0; l&apos;&#xE9;chelle internationale s&apos;inscrit surtout dans le cadre de l&apos;Initiative canadienne de vaccin contre le VIH (ICVV). Celle-ci comporte quatre volets : 1) la mise au point de nouveaux vaccins contre le VIH et d&apos;autres approches de pr&#xE9;vention; 2) l&apos;examen des questions sociales et relevant des politiques qui sont li&#xE9;es au VIH/sida; 3) la r&#xE9;alisation d&apos;essais cliniques; et 4) la construction d&apos;une usine de fabrication du vaccin contre le VIH au Canada. Le troisi&#xE8;me volet (les essais cliniques) exige la participation d&apos;&#xE9;tablissements de recherche de partout dans le monde, notamment ceux des pays o&#xF9; la pr&#xE9;valence du VIH est &#xE9;lev&#xE9;e. Or, bien souvent, ces &#xE9;tablissements, surtout ceux d&apos;Afrique, ne disposent pas des capacit&#xE9;s de recherche voulues pour participer pleinement &#xE0; ces essais.

Afin d&apos;y rem&#xE9;dier, l&apos;Agence canadienne de d&#xE9;veloppement international (ACDI) a accord&#xE9; 6 millions de dollars canadiens &#xE0; l&apos;Initiative de recherche en sant&#xE9; mondiale (IRSM) en 2009 afin de lui permettre de soutenir le renforcement des capacit&#xE9;s des &#xE9;tablissements africains de faire des essais cliniques. L&apos;ACDI participe tant &#xE0; l&apos;ICVV qu&apos;&#xE0; l&apos;IRSM. Le pr&#xE9;sent projet fera fond sur les travaux amorc&#xE9;s dans le cadre du projet Renforcement des capacit&#xE9;s en vue d&apos;essais relatifs &#xE0; la pr&#xE9;vention du VIH/sida (no 104051), puis du projet Subventions de renforcement des capacit&#xE9;s en vue d&apos;essais en mati&#xE8;re de pr&#xE9;vention du VIH/sida - phase II (no 105704).</narrative>
   <narrative xml:lang="EN">In December 2007, the United Nations Joint Programme on HIV/AIDS estimated that approximately 33.2 million people were living with HIV worldwide, 68% of them in Africa, where AIDS is the leading cause of death. Canada&apos;s response to the international HIV/AIDS epidemic is largely built around the Canadian HIV Vaccine Initiative (CHVI). The Initiative comprises four components: 1) developing new HIV vaccines and other preventive approaches; 2) conducting research on social and policy issues related to HIV/AIDS; 3) conducting clinical trials; and 4) building an HIV vaccine manufacturing facility in Canada. The third component, conducting clinical trials, requires the participation of research institutes around the world, including those operating in high-prevalence countries. However, such institutions, especially those in Africa, often lack the research capacity needed to fully engage in clinical trials. In order to address this challenge, the Canadian International Development Agency (CIDA) has allocated CA $6 million to the Global Health Research Initiative (GHRI) to build African capacity for clinical trials in 2009. CIDA is a member of both CHVI and GHRI. This project will build on work carried out under an earlier effort, Capacity Building for HIV/AIDS Prevention Trials (104051), and under a more recent project, HIV/AIDS Prevention Trials Capacity Building Grants (105704).</narrative>
  </description>
  <participating-org role="2" type="23">
   <narrative xml:lang="EN">Botswana-Harvard Aids institute</narrative>
  </participating-org>
  <participating-org role="4" type="23">
   <narrative xml:lang="EN">Botswana-Harvard Aids institute</narrative>
  </participating-org>
  <participating-org role="3" type="15">
   <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
   <narrative xml:lang="ES">Centro Internacional de Investigaciones para el Desarrollo</narrative>
   <narrative xml:lang="EN">International Development Research Centre</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2010-01-12" type="2"></activity-date>
  <activity-date iso-date="2010-04-12" type="4"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
    <narrative xml:lang="EN">International Development Research Centre</narrative>
   </organisation>
   <telephone>(+1) 613-236-6163</telephone>
   <email>info@idrc.ca</email>
   <website>http://www.idrc.ca</website>
   <mailing-address>
    <narrative xml:lang="FR">CP 8500, Ottawa ON Canada, K1G 3H9</narrative>
    <narrative xml:lang="EN">PO Box 8500, Ottawa ON Canada, K1G 3H9</narrative>
   </mailing-address>
  </contact-info>
  <activity-scope code="2"></activity-scope>
  <recipient-region code="X7" percentage="100" vocabulary="1"></recipient-region>
  <sector code="00001" percentage="100" vocabulary="99">
   <narrative xml:lang="FR">Autre</narrative>
   <narrative xml:lang="EN">Other</narrative>
  </sector>
  <sector code="12182" percentage="100" vocabulary="1"></sector>
  <policy-marker code="1" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="5" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1"></policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <conditions attached="1">
   <condition type="2">
    <narrative xml:lang="EN">Grant is conditional on completion of specified terms of reference</narrative>
    <narrative xml:lang="FR">La bourse est octroy&#xE9;e &#xE0; condition de respecter le mandat &#xE9;tabli</narrative>
   </condition>
   <condition type="3">
    <narrative xml:lang="EN">Grant is conditional on minimal accounting of funds received (e.g. proof of attendance at workshop)</narrative>
    <narrative xml:lang="FR">La bourse est octroy&#xE9;e sur justification minimale des fonds re&#xE7;us (p.ex., preuve de participation &#xE0; un atelier)</narrative>
   </condition>
   <condition type="3">
    <narrative xml:lang="EN">Grant is conditional on submission of simple accounting of funds received (e.g. submission of organization&apos;s annual report).</narrative>
    <narrative xml:lang="FR">La bourse est octroy&#xE9;e &#xE0; condition de pr&#xE9;senter une simple justification des fonds re&#xE7;us (p.?ex., pr&#xE9;sentation du rapport annuel de l&apos;organisation).</narrative>
   </condition>
  </conditions>
 </iati-activity>
</iati-activities>
